How senescence inhibitors are finally making it into clinical trials, and why it took so long
Cellular senescence has been one of the most promising targets in aging science for years. Yet the road from the laboratory to clinical use has turned out to be unusually rough. An expert panel explains why, and what is changing now.
Lifespan.io has published an in-depth expert roundtable on cellular senescence and senotherapeutics, the agents designed either to clear senescent cells (senolytics) or to dial down their damaging secretions (senopmorphics). The participants are researchers and clinicians active in the field, and their answers reveal just how many open questions remain, even after two decades of intense research.
Senescent cells are cells that have stopped dividing but refuse to die. They accumulate in tissues as we age and chronically secrete pro-inflammatory compounds known collectively as the SASP. In animal models, senolytics have delivered impressive results: less tissue damage, better physical function, and extended lifespan across multiple models. The leap to humans has been slower than anyone hoped.
Why clinical trials are so hard to run
A core problem is the absence of good biomarkers. To test whether a senolytic is actually working, you need to be able to measure how many senescent cells are present before and after treatment. No reliable, standardized way to do that exists yet in humans. Plasma SASP factors are used as a proxy, but they are not specific enough: the same cytokines are elevated during infection, metabolic stress, and a wide range of other conditions. Running a trial without a dependable outcome measure is a risky proposition.
A second problem is selectivity. The most widely used senolytics, combinations such as dasatinib plus quercetin, or navitoclax, are not exclusive: they can hit non-senescent cells as well. Navitoclax is a potent senolytic, but it also lowers platelet counts, which limits its clinical utility. Rubedo Life Sciences, which recently reported positive Phase 1 results for RLS-1496 in skin conditions and aged skin, is working on more selective molecules. That is an encouraging signal, though so far it applies to the skin rather than deeper tissues.
Where experts agree and where they do not
The panel agrees on the theory: senescent cells contribute to aging and age-related disease, and they are in principle removable. On the practical questions, opinions diverge sharply. When should you treat, early as a preventive measure, or only once disease has already appeared? Which tissue do you prioritize? How often does treatment need to be repeated? And is clearing senescent cells always desirable, given that they also play useful roles in wound healing and tumor suppression? The field is further along than it was ten years ago, but the clinical breakthrough that once seemed just around the corner has yet to arrive.